Deveron Reports Fiscal Q2/2025 Financial Results

In This Article:

Toronto, Ontario--(Newsfile Corp. - February 28, 2025) - Deveron Corp. (TSXV: FARM) ("Deveron" or the "Company"), a leading agriculture services and data company in North America, is pleased to report results for the three- and six- months ended December 31st, 2024. Full financial results are available at www.sedarplus.ca.

On February 25, 2025, the Company filed a revocation application to revote the failure to file cease trade order ("CTO") issued by the Ontario Securities Commission ("OSC") against the Company dated November 1, 2024. The CTO orders that general trading, whether direct or indirect, of the securities of the Company cease. A copy of the CTO has been posted on the Company's SEDAR+ profile at www.sedarplus.ca. The Company will provide further updates as they become available.

Second Quarter 2025 Financial Highlights

Revenue for Fiscal Q2/2025 decreased 22% to $11,901,189 from $15,308,397 in the same period in the prior year. Fiscal Q2/2025 Non-IFRS Adjusted EBITDA decreased 39% to $3,413,075 in Q2/2025 from $5,628,224 in the same period in the prior year. Fiscal H1/2025 Non-IFRS Adjusted EBITDA decreased 31% to $3,136,564 from $4,678,149 in the same period in the prior year. Revenue for Fiscal H1/2025 decreased 17% to $19,137,646 from $23,026,999 in the same period in the prior year. These changes in revenue are largely due to softer sales in the Company's fertility and specialty tissue products in Canada, the macroeconomic effects currently affecting the North American agricultural industry, and the Company's exit from its unprofitable carbon business. Adjusted EBITDA was more greatly affected due to volume decreases in the Canadian operation. The Canadian operation has a higher margin profile for its fertility and speciality tissue testing products, which drove the higher impact to EBITDA in the quarter.

Operating expenses decreased by 22% to $7.24M. Of this reduction, 16% resulted from the previously announced cost optimization efforts and headcount reductions in the US operations and at the corporate level. The remaining 9% reflects changes in non-cash items, including the NCI put obligation, depreciation, and share-based payments. The company's Non-IFRS adjusted EBITDA margin percentage declined by 8.1% year-over-year to 28.7% from 36.8% in the similar period in FY2024. Gross profit margin decreased from 74% to 68%, driven by inflationary price increases for laboratory supplies and lower volumes of the Company's higher-margin testing products in Canada.